business#Sales_to_assets_ratio
Novo_Nordisk#1.0
Roche#0.8
Merck_&_Co.#0.6
GlaxoSmithKline#0.5
Johnson_&_Johnson#0.5
Biogen#0.5
Lilly#0.5
Novartis#0.4
Gilead#0.4
AbbVie#0.4
Amgen#0.4
AstraZeneca#0.4
Mylan#0.4
Teva#0.3
Bristol-Myers_Squibb#0.3
Pfizer#0.3
Sanofi#0.3
Endo#0.3
